SEI Investments’s Galectin Therapeutics GALT Stock Holding History

SEI Investments’s Portfolio GALT Stock Details GALT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-3,800	Closed	-$24K	–	2831
2018 Q2	$24K	Hold	3,800	–	–	﹤0.01%	2738
2018 Q1	$18K	Hold	3,800	–	–	﹤0.01%	2680
2017 Q4	$13K	Hold	3,800	–	–	﹤0.01%	2717
2017 Q3	$8K	Hold	3,800	–	–	﹤0.01%	2740
2017 Q2	$9K	Buy	+3,800	New	+$10.1K	﹤0.01%	2606

Other funds holding GALT

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

DADC

D.A. Davidson & Co Great Falls, Montana $16.5B AUM 19.94% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Advisor Group Phoenix, Arizona $14.5B AUM 24.86% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

FFA

First Foundation Advisors Irvine, California $2.48B AUM 18.56% 1-Year Est. Return

BCA

Benchmark Capital Advisors New York $101M AUM 0.8% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Bank of Montreal Toronto, Ontario, Canada $269B AUM 31.4% 1-Year Est. Return

SEI Investments's GALT Position: Q3 2018 in Review

SEI Investments sold out of Galectin Therapeutics (GALT) in Q3 2018, closing a stake of 3,800 shares — an estimated $24K sold.

SEI Investments first reported a position in GALT in Q2 2017 and held it in 5 quarters. The position peaked at $24K in Q2 2018. 60 funds tracked by Wall St. Rank hold GALT as of Q3 2018.

SEI Investments reported no remaining Galectin Therapeutics position as of Q3 2018 after selling out during the quarter.
SEI Investments sold 3,800 Galectin Therapeutics shares in Q3 2018, an estimated $24K.
SEI Investments first reported a position in Galectin Therapeutics in Q2 2017 and held it in 5 quarters.
SEI Investments's Galectin Therapeutics position peaked at $24K in Q2 2018.
60 funds tracked by Wall St. Rank held Galectin Therapeutics as of Q3 2018.

Based on SEI Investments's 13F filing for Q3 2018, filed 8 Nov 2018.